Middle East and Turkey Hemophilia Treatment Market, By Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), By Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and By Country (Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East)-

Published In : Apr 2023

Code : CMI3250

Pages :230

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Middle East and Turkey Hemophilia Treatment Market– Drivers

Increasing Inorganic Growth Strategies Such As Agreement

Increasing inorganic growth strategies such as agreement by key market players to expand their product portfolio is expected to drive the market growth over the forecast period. For instance, in May 2021, CSL Behring, a pharmaceutical company, announced license agreement with UniQure N.V., a healthcare company, for etranacogene dezaparvovec (AMT-061), a novel gene therapy for the treatment of hemophilia B. Etranacogene dezaparvovec is currently in Phase 3 clinical trials for hemophilia B.

Increasing Prevalence Of Hemophilia

Increasing prevalence of hemophilia in Turkey is expected to drive the market growth over the forecast period. For instance, in June 2020, according to data published by the Journal Transfusion and Apheresis Science, in 2018, the percentage of von Willebrand disease (vWd), hemophilia and rare bleeding disorders (RBD) were 40 %, 34 % and 26 %, type-1, type-2 and type-3 vWd were 63 % 17 % and 20 %, hemophilia A and B were 84 % and 16 %, and severe, moderate and mild hemophilia were 48 %, 30 % and 22 %, in Turkish children respectively.

Middle East and Turkey Hemophilia Treatment Marke- Restraint

High Cost of Hemophilia Drugs

High costs of Hemophilia drugs, lack of skilled professionals, and stringent rules and regulations for product approval are the major factors that can hamper the market growth over the forecast period. For instance, in December 2021, according to the data provided by National Library of Medicine, Hemophilia A has a significant economic burden in Turkey due to costlyreplacement therapy. The major cost contributor was factor replacement therapy. With inhibitor development, the average annual cost increased more than 3-fold. In 2018, the total annual disease burden of hemophilia A in turkey was US$ 614 million, which was 1.6% of the total health expenditure in Turkey